Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KT-621 in Moderate to Severe Atopic Dermatitis
NCT07217015Phase 2Active, not recruiting
- Sponsor
- Kymera Therapeutics
- Start
- Nov 2025
- Primary completion
- Jun 2027
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 8
01
Overview
A Phase 2 trial of KT-621 in atopic dermatitis (AD), sponsored by Kymera Therapeutics. Started Nov 2025; status: active, not recruiting.
02
Drugs
KT-621
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07217015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07217015.